Freenome

Today is World Lung Cancer Day, a time to raise awareness and support those affected by lung cancer, the leading cause of cancer deaths worldwide. At Freenome, we are developing blood tests to detect lung cancer early, when it is most treatable. The PROACT LUNG Study is intended to validate the clinical performance of a blood-based test for the early detection of lung cancer. We are currently enrolling as many as 20,000 individuals who meet specific criteria. Together, we can drive significant progress in early cancer detection. #WLCD24 #EarlyDetection #Freenome

Earlier this week, our CEO, Mike Nolan, shared his perspectives on how liquid biopsy innovations are reshaping cancer care at the 2024 Analytical, Life Science & Diagnostics Association (ALDA) Spring Senior Executive Conference in London:   “Blood-based technologies have vast potential to improve how we diagnose cancer, make treatment decisions, and monitor for disease resistance. Getting these tools into the clinic requires strong collaboration between life sciences and diagnostic companies. By working together with a shared purpose, we are determined to improve patient outcomes with innovations in liquid biopsy technologies - and set new standards of cancer care.”

We look forward to joining our colleagues and peers at Digestive Disease Week 2024 in Washington, D.C., May 18-21, where we will share our latest research in early cancer detection. If you are attending, stop by Booth 3351 to learn more about our work to outpace cancer.

Today, we want to take a moment to express our deepest gratitude to our incredible team members who are the driving force behind Freenome’s mission. As we continue to build our early cancer detection platform and advance the best portfolio of blood-based tests to meet the needs of patients, we are optimizing our structure and resources. We are confident in the role our blood-based tests will have in leveling the playing field for all people who need access to recommended cancer screenings. After thoughtful consideration, we have made the difficult decision to restructure our organization to better align with our strategic priorities. Unfortunately, this will eliminate some roles, impacting approximately 20% of our colleagues across multiple functions. We extend our appreciation to these individuals for being integral to our journey and for contributing to this remarkable team. We understand that these transitions bring challenges, and we are committed to supporting impacted team members through this process. If you are looking for talented and passionate individuals who have been instrumental in building a great culture, please reach out to [email protected]. We appreciate your help in finding them their next opportunity.

Today, we announced topline results from our PREEMPT CRC Study, the largest clinical study to validate a blood-based test for the early detection of colorectal cancer. Read more in the press release here: https://lnkd.in/gr3PgG89

Understanding who is at high risk for colorectal cancer is important for early detection. While the American Cancer Society advises regular screening starting at age 45 for those at average risk, earlier and more frequent screening is advisable for those at higher risk due to factors like family history or certain medical conditions, e.g., Crohn's disease.   #ColorectalCancerAwareness #Freenome #EarlyCancerDetection

According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer for both men and women. Their recent extrapolations put the estimated number of diagnosed CRC cases in the United States for 2024 at more than 150,000.   According to our CEO Mike Nolan, “When you look at people who were diagnosed with colorectal cancer, and you look historically at when they were screened for colorectal cancer– they weren’t, all too often." We intend to change that scenario by developing blood tests for early cancer detection.   #EarlyCancerDetection #CancerScreening #GetScreened

Freenome was founded in 2014, and now in 2024, we are entering our next decade with a refreshed look.   While our appearance has changed, our mission has not. We remain committed to outpacing cancer through early detection, by combining the latest in science and artificial intelligence to create accessible screening tests. To see more, visit: https://freenome.com   #Freenome #EarlyCancerDetection

This March, in observance of Colorectal Cancer Awareness Month, we reaffirm our commitment to battling colorectal cancer (CRC) through our work building early cancer detection blood tests. Throughout March, we'll share more about CRC, and spotlight the potential of early detection to save lives. #ColorectalCancerAwareness #Freenome #EarlyCancerDetection 

Today, we announce the closure of a $254 million funding round led by Roche alongside existing and new investors. Their strategic investment will accelerate our efforts to advance early cancer detection. This funding demonstrates our collective commitment to transforming cancer care by helping make early cancer detection "more convenient, accessible and actionable for everyone," in the words of our CEO Mike Nolan. Detecting cancer too late is contributing to its high mortality rate. This is epitomized by colorectal cancer, which is highly treatable if caught early. At Freenome, we are determined to change this dynamic by integrating computational biology, machine learning, and other technologies to detect cancer early—when it is most treatable. Learn more: https://lnkd.in/g_v2zsxN #Freenome #EarlyCancerDetection #CancerResearch #HealthcareInnovation